Abbott Laboratories (NYSE:ABT) Posts Quarterly Earnings Results, Hits Expectations

Abbott Laboratories (NYSE:ABT) released its quarterly earnings results on Wednesday. The healthcare product maker reported $0.95 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.95, RTT News reports. The firm had revenue of $8.31 billion for the quarter, compared to analyst estimates of $8.26 billion. Abbott Laboratories had a net margin of 11.56% and a return on equity of 18.34%. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.81 EPS.

Abbott Laboratories stock opened at $90.73 on Friday. Abbott Laboratories has a twelve month low of $68.80 and a twelve month high of $92.45. The stock’s fifty day simple moving average is $86.80 and its 200-day simple moving average is $84.76. The company has a current ratio of 1.54, a quick ratio of 1.12 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $162.45 billion, a P/E ratio of 44.04, a P/E/G ratio of 2.36 and a beta of 1.12.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be given a dividend of $0.36 per share. The ex-dividend date is Tuesday, January 14th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.59%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.32. Abbott Laboratories’s dividend payout ratio is currently 44.44%.

Several analysts have recently commented on ABT shares. William Blair reaffirmed an “underperform” rating on shares of Abbott Laboratories in a research report on Thursday, October 17th. Evercore ISI lowered Abbott Laboratories from an “outperform” rating to an “in-line” rating in a research report on Thursday, January 2nd. Citigroup lowered Abbott Laboratories from a “neutral” rating to a “sell” rating in a research report on Thursday, January 2nd. Wells Fargo & Co boosted their target price on Abbott Laboratories from $97.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Morgan Stanley boosted their target price on Abbott Laboratories from $93.00 to $101.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $95.20.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Featured Article: What is a back-end load?

Earnings History for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with's FREE daily email newsletter.